First study of neoadjuvant use of PARP inhibitor shows promise for...
In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD...
Erdafitinib shows promise in urothelial cancer patients...
In an international Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with the oral...
Study of acute myeloid leukemia patients shows protein...
Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in...
Long-term IMPACT data find improved survival when targeted...
Matching targeted therapies to tumor-specific gene mutations across tumor types improved progression-free survival (PFS) and overall...
MD Anderson Informs Patients of Accidental Disclosure of Email...
The University of Texas MD Anderson Cancer Center today sent letters to individuals whose email addresses were accidentally exposed in...
MD Anderson and Amgen to accelerate early-stage treatments for...
The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at...
ASCO honors MD Anderson faculty with awards
The American Society of Clinical Oncology (ASCO) will present awards to leaders of cancer care during its annual meeting June 1-5 in...
MD Anderson and Ipsen announce joint bench-to-bedside...
The University of Texas MD Anderson and Ipsen, a global biopharmaceutical group, today announced a global licensing and joint...
Nursing Leaders from MD Anderson Cancer Center, Seattle Cancer...
While some regions of the nation will experience greater nursing shortages than others in the coming years, hospitals and healthcare...
Surveillance intensity not associated with earlier...
A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between...
Self-reporting with sensor and mobile technology may reduce...
Abstract: 6063
A study led by researchers at The University of Texas MD Anderson Cancer Center found that the use of at-home sensor...
New approach to cancer research aims to accelerate studies...
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and...
Preclinical MD Anderson study suggests ARID1a may be useful...
Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize...
MD Anderson, Spectrum Pharmaceuticals complete poziotinib...
The University of Texas MD Anderson Cancer Center and Spectrum Pharmaceuticals have signed a licensing agreement that covers...